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Abstract: New  Delhi,  an  enzyme  belonging  to  the  Metallo-beta-lactamases  and
Carbapenemases group, is most commonly found in Klebsiella pneumoniae and Escherichia
coli. It determines these bacteria resistance to the majority of known antibiotics. NDM-1 was
discovered  in  2008  in  a  man  treated  in  New Delhi  for  E.  coli  infection.  Since  the  first
appearance,  17  subtypes  of  this  enzyme  have  been  discovered.  Its  occurrence  has  been
reported in Europe (Great Britain, France, Belgium - where even a national alert has been
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issued)  as  well  as  in  the  United  States  and in  Africa.  Most  cases  of  New Delhi  enzyme
bacterial infections are reported in India or in people who have traveled to this country. There
is no treatment method described so far. Therapy is based on antibiotic  susceptibility  test
results. Colistin shows the highest effectiveness against NDM. There are also tests suggesting
that Isomargololone and Nimbolide may be effective in most cases of NDM infection.
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1. Introduction
New  Delhi  Metallo-beta-lactamases  (NDM)  are  the  enzymes  that  are  found  mainly  in
Enterobacteriae - Klebsiella  pneumoniae and Escherichia  coli,  but may also be present in
other  genera.  The most  common is  NMD type  1  (NDM-1).  Its  presence  determine  these
bacteria resistance to all beta-lactam antibiotics. NDM was first described in 2008. India is the
main source of infection, but the problem with pathogens carrying these enzymes affects the
whole world.
2. Metallo-beta-lactamase
These  enzymes  belong  to  carbapenemases,  which  contain  metal-zinc  in  their  structure.
Hydrolysis is its mechanism of resistance to penicillins, cephalosporins, and carbapenems.
However,  they  are  still  susceptible  to  monobactams.  Most  of  them are  resistant  to  beta-
lactamase inhibitors, however, they are inhibited by EDTA (edetic acid). This susceptibility is
not  demonstrated  by  other  beta-lactamases  because  they  lack  metal  component  in  their
structure [30, 41].
Metallo-beta-lactamases  are  classified  according  to  the  1995 proposal  of  Bush et  al.  into
group 3 and molecular class B [3, 31]. The internal classification of carbapenemases, based on
a number of functional and molecular features, divides it into groups A, B, C and D. Table 1
depicts all the groups, together with their representatives [41].
TAB.1
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B (metallo- beta- lactamases) NDM
VIM
C CMY
D (CHDL-carbapenem-hydrolyzing class D
β-lactamases)
OXA
[18, 22, 29, 31, 40, 41]
3. NMD-1 structure
The bla  NMD-1 gene encodes  a  single chain polypeptide,  built  of 269 amino acids  with
molecular mass of about 27.5 kDa. It is actively present as a monomer with an approximate
mass of 28 kDa. The enzyme contains a leader peptide in its structure. It contains a unique
additional  sequence at  positions 162-166 bla NMD-1 numbering.  On the one hand, it  has
hardly common features with other Metallo-beta-lactamases, but on the other, it contains zinc
like the rest of them. It is the most closely related to VIM-1 [14] and VIM-2 [54] produced by
K. pneumoniae and Acinetobacter baumanii. The identity is 32.4% [23, 59].
4. Discovery
In 2008, Young et al. presented a report on the IDSA-Infectious Diseases Society of America
about the identification of a new Metallo-beta-lactamase group. It was isolated from a 59-
year-old  patient  treated  in  India,  New  Delhi,  hence  the  name  of  the  enzyme.  He  was
diagnosed  with  a  Klebsiella  pneumoniae  urinary  tract  infection.  Following  the  results  of
susceptibility testing, it was found that the isolate was resistant to all beta-lactam antibiotics.
It  was  susceptible  to  only one beta-lactam-  aztreonam plus  colistin  and fluoroquinolones.
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After microbiological analysis, the bacterial enzyme was classified into the metal-lactamase
B1 subgroup [44, 55, 59].
5. Threat
Consecutive cases of infections caused by bacteria containing abovementioned enzymes were
reported in the UK [33] and in the US [6] in 2010 and in South Africa in 2011 [2]. Although
patients had previously visited India in the first two cases, disease is not confined to this one
particular region but affects the whole world. In Belgium, a national alert was issued in 2010
due  to  the  NDM  isolation  [1].  In  subsequent  years  there  have  been  reports  of  bacteria
producing those enzymes in various parts of the world [12, 19, 39]. Travelling from India to
other countries may play an important role in NMD spreading [28]. 
This  enzyme is  also  a  significant  problem because  of  the  asymptomatic  carriers,  lack  of
effective pharmacotherapy and its potential presence among many Gram-negative bacteria. Its
existence has been identified in for instance: Providencia spp. (for example P. rettegri)  [25],
Proteus spp., Klebsiella oxytoca, Citrobacter freundii, Morganella morgani  [44], Salmonella
enterica [4] and Acinetobacter baumanii [17]. In 2010, Kumarasamy et al. presented a report
about  180  cases  of  New  Delhi's  (NMD-1)  isolates.  111  of  them  were  identified  in  K.
pneumoniae and 36 in E. coli [24]. 
Bacteria  with  NMD-1  may  be  responsible  not  only  for  urinary  tract  infections  but  also
diarrhea, peritonitis, lung infections, sepsis, and soft tissue infections [37]. The disease is not
age specific. There are cases of infection among pediatric patients [32], including newborns
[45].  Seema et al.  found that the majority (35.1%), of NDM bacterial  infections,  occur in
patients hospitalized in intensive care units [46]. The youngest patient in their study, infected
with NDM, was one day old, and the oldest was 85 years old. 
NDM-containing pathogens are also capable of infecting animals [47]. Yousfi et al. described
the case of an E. coli NDM-5 infection in Algerian dog [60]. 
Walsh et al. published the results of water tests from New Delhi. They collected tap water,
seepage and sewage effluent samples. The NMD-1 gene was detected in two of 50 drinking-
water samples and in 51 of 171 seepage samples.  This indicates the capital  of India as a
particularly dangerous source of pathogens containing NMD-1 enzyme [56]. 
In addition, it was found that the carriage by Enterobacteriae spp., Aeromonas spp. and Vibrio
cholerae was stable and associated with resistance patterns typical for NMD-1. Unstable gene
transmission occurred in non-fermenting bacteria. The best temperature for transfer turned out
to be 30 ° C. Researchers identified 20 different strains of microorganisms in the samples, 12
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of which carried genes on plasmids and two of them (Vibrio cholerae and Aeromonas caviae)
on chromosomes [56]. 
In 2011, a Canadian woman was diagnosed with K. pneumoniae, after visiting India. Initially,
diarrhea appeared during her stay in this Asian country. Then congestive heart failure and
hypertension  developed.  She  was  readmitted  to  the  hospital  later  due  to  unspecified
encephalitis,  decreased consciousness, urinary tract infection,  and ongoing diarrhea.  There
was  also  a  fever  and a  blood  pressure  100/80 mm Hg.  Urine  culture  grew highly  drug-
resistant K. pneumoniae (colistin-sensitive) and stool specimen was positive for Clostridium
difficile.  After  some  time,  E.  coli  beta-lactamase  (+)  co-infection  was  also  confirmed.
Ultimately, after the attempts of combined treatment with antibiotics, the patient died. This is
a proof that NDM-1 pathogens infections can be very severe, involving many systems, and
that the co-infection may occur [34]. 
Another  case  was  75-year-old  patient  from  the  UAE.  He  presented  with  pneumonia,
respiratory failure, stroke and septic shock. The causative agent was NMD-5 producing K.
pneumonia and was contained by colistin and meropenem [8]. 
Some bacteria containing the bla NDM gene, have a ble MBL gene encoding a BRP MBL
protein that determines resistance to bleomycin [10]. This gene, which determines antibiotic
resistance,  may also coexist  with the bla  OXA 48 and bla  OXA 181 genes,  respectively
forming enzymes: OXA 48 and OXA 181 [5, 11, 50].
6. NDM variants
NDM occurs in several variants. The main type is NDM-1, but recently there has been also
NDM-2, NDM-3 [43], NDM-4 (differing from NDM-1 by a single amino acid substitution at
position 154) [35], NDM-5 described. Hornsey et al. described a case of multidrug-resistant
E. coli ST648 isolate, designated EC405. Researchers have come to the conclusion that they
stumbled  upon  a  new subtype  of  New Delhi  Metallo-beta-lactamase.  This  variant  of  the
enzyme differed from existing enzymes due to amino acids substitutions at positions 88 and
154, and reduced susceptibility to antibiotics. This discovery took place in 2011 in the UK
(the patient was previously hospitalized in India). In addition, EC405 was found to contain
part of IS Aba125, most likely derived from Acinetobacter baumanii [16]. 
NDM-2 was isolated from Acinetobacter baumanii. The first reports of this variant appeared
in 2011. The bla NDM-2 gene is surrounded by two copies of IS Aba 125. Compared to
NDM-1 in NDM-2 there is an amino acid substitution at positions 28 and 82. 
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Espinal et al. reported the identification of this variant in Israel and Kaase et al. described it in
Egypt in patients with no previous travel or hospitalization on the Indian subcontinent  [13,
20]. 
Rahman et al. asserted that up until 2014, seven types of NDM (1-7) had been identified.
They examined 464 samples from India and claimed that NDM 5-7 is more common in E.
coli, and more common in patients hospitalized for urological reasons. The NDM-7 enzyme
also appeared in Europe – f.eg. in France and in Germany [9, 15, 42]. 
NDM-8 have been found in E. coli isolated from the respiratory tract of Nepali patient. This
variant differed from NMD-1 by substitution at positions 130 and 154 [51]. 
In 2014, Wang et al.  described the new NDM-9 variant.  The enzyme was detected in K.
pneumoniae in China [57]. 
In  2016,  Yao  et  al.  reported  NDM-9  detected  in  E.  coli  (colistin  resistant),  which  also
produced MCR-1 and Khajuria et al. detected NDM-10 in K. pneumoniae isolate [21, 58]. 
NDM-12 and NDM-13, produced by E. coli, have also been described, both in Nepal [49, 52].
The first variant showed differences in the amino acid sequences (from NMD-1) at positions
154 and 222. The NDM-12 bla gene was located on a plasmid. The second subtype gene,
NDM-13, was found on chromosomes. Changes when comparing to NDM-1 were at positions
95  and  154.  NDM-14  was  also  isolated  from  Acinetobacter  lwolffi  in  China  [61].  It
demonstrates a single change (vs. NMD-1) in the amino acid sequence – at a position 130. 
In 2017 a variant 17 of the New Delhi enzyme was discovered. It was identified in E.coli
strain  from  chicken  in  China.  Compared  to  NDM-1,  NDM-17  had  three  amino  acid
substitution (positions 88, 154, 170) that significantly increased their carbapenemase activity
[27].
7. Treatment
This enzyme determines bacteria’s resistance to all beta-lactam antibiotics.  In some cases,
they are susceptible to aztreonam, but usually, they produce beta-lactamase that hydrolyzes it
[48]. 
In the treatment  of NDM-containing bacteria,  there is  no particular  algorithm or standard
antibiotic therapy. In the enzyme presence - susceptibility test should be made, to look for
effective  treatment.  There  are  some examples  of  infections  incidents  and treatment  listed
below. 
In 2013, Rogers et al. reported two cases of urinary tract infection with Enterobacteriaceae
harboring New Delhi bla NDM-1 genes (Enterobacter cloacae) and previously undescribed
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enzyme variant bla NDM-3 (Escherichia coli). Both patients lived in Australia and traveled to
the Indian Subcontinent. Oral therapy with nitrofurantoin was successful in one case, while a
combination of colistin and rifampicin was required in the second patient. [43]. 
Muir  et  al.  described a  case of NMD-1 bacterial  infection  in  the United Kingdom. After
performing susceptibility testing, they found that the microorganism was completely resistant
to all antibiotics except for colistin and tigecycline [33]. 
In 2012, Nordmann et al. described a case of a woman from southern France, with cystitis due
to  K.  pneumoniae,  harboring  NDM-1  and  CTX-M-15  genes  located  on  two  different
plasmids.  Neither this patient nor her husband had traveled to any country in the previous 3
years,  including  countries  with  a  high  prevalence  of  NDM-1  producers.  She  also  denied
having a diet containing Indian food. It may correspond to the ultimate spread of NDM-1
producers worldwide - outside its main reservoir. The Vitek-2 automated susceptibility testing
showed multidrug resistance.  However,  the pathogen exhibited susceptibility to antibiotics
such as fosfomycin, colistin, tetracycline, amikacin, and tigecycline [36]. 
Peirano  et  al.  presented  a  case  of  a  young  man  who  reported,  as  did  the  other  patients
mentioned above in this review, a trip to India in an interview. Pyelonephritis and prostatitis
caused  by  NDM-1  producing  E.coli  were  diagnosed.  Antimicrobial  drug  susceptibility
determined with the VITEK 2 and Etest AB Biodisk confirmed the multiresistant nature of
these  bacteria.  Fortunately,  the  patient  was  successfully  treated  with  ertapenem  and
fosfomycin  combination  therapy  (even  though  in  the  Vitek-2  E.  coli  MH01 test  showed
resistance  to  ertapenem  and  sensitivity  to  tigecycline  and  fosfomycin)  [38].
Chen et al analyzed more than 11,000 E. coli, K. pneumoniae, A. baumanii and P. aeruginosa
isolates. The bla NDM-1 gene was detected on plasmids of 4 strains of A. baumanii. Analysis
showed that three of them were sensitive to aminoglycosides, fluoroquinolones and colistin
[7]. 
Lascols et  al.  analyzed the effects  of antibiotics on strains carrying the bla NDM-1 gene.
72.7% were susceptible to colistin and 69.7% to tigecycline. Whereas 9.1% were resistant and
51.5% were susceptible to both of them [25]. 
Abovementioned  findings  suggest  that  each  NMD  producer  is  sensitive  to  different
antibiotics,  thus  each  infection  should  be  treated  individually  accordingly  to  antibiotic
susceptibility  testing  result.  Although colistin  is  the  most  effective  drug,  it  is  not  a  gold
standard and there are cases of resistance as in NDM-9 [26, 57] due to the presence of MCR-
1. 
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Currently, there are ongoing studies to find a drug effective in New Delhi enzymes producers
treatment. Tests have shown that Nimbolide and Isomargololone have a high affinity to NDM,
and may be effective NDM inhibitors [53].
8. Summary
Bacteria  carrying  NDM enzymes  are  an  important  clinical  problem.  Recently  discovered
Metallo-beta-lactamase  New  Delhi  group  is  more  commonly  occurring  and  differ  in  its
variants. Up to date, infections by several forms had been described. Due to its multidrug
resistance, New Delhi infections are associated with severe clinical outcomes, often resulting
in death and making it difficult to find effective treatment. Moreover, these enzymes, though
predominantly occurring in E. coli and K. pneumoniae, can be produced by many bacteria and
the infections may have a different course and affect any age group. However, there is an
ongoing  search  to  find  an  inhibitor  that  offers  the  chance  for  effective  treatment.
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